Medical device company, Tepha, has entered a royalty obligations agreement with pharmaceutical company, Metabolix, to use the latter’s biopolymer technology in certain medical applications.

As part of the agreement, which also includes two additional Metabolix production strains and related IP, Tepha will pay Metabolix $2m in order to avoid future royalties.

HTG Molecular Diagnostics and Merck KGaA have signed a broad companion diagnostics master agreement.

"Tepha will pay Metabolix $2m in order to avoid future royalties."

The initial development programme under the agreement involves using the former’s EdgeSeq DLBCL cell of origin assay in the latter’s development programme of M7583, a selective and irreversible inhibitor of Burton’s Tyrosine Kinase (BTK).

Midatech Pharma has raised £16m ($19.83m) through a private placement of its common stock shares, which was oversubscribed to by its existing and new investors.

The company has also raised £12m ($14.87m) in another private placement of its common stock shares.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The proceeds will be used by the company to expand and advance product development pipeline, to invest in its manufacturing and commercial platform and for working capital expenses.